1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 United States Cancer Biomarkers Market - Introduction
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 United States Cancer Biomarkers Market Landscape
5.1 Historical and Current Market Trends (2018-2023)
5.2 Market Forecast (2024-2032)
6 United States Cancer Biomarkers Market - Breakup by Profiling Technology
6.1 Omic Technologies
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2018-2023)
6.1.3 Market Forecast (2024-2032)
6.2 Imaging Technologies
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2018-2023)
6.2.3 Market Forecast (2024-2032)
6.3 Immunoassays
6.3.1 Overview
6.3.2 Historical and Current Market Trends (2018-2023)
6.3.3 Market Forecast (2024-2032)
6.4 Cytogenetics
6.4.1 Overview
6.4.2 Historical and Current Market Trends (2018-2023)
6.4.3 Market Forecast (2024-2032)
7 United States Cancer Biomarkers Market - Breakup by Biomolecule
7.1 Genetic Biomarkers
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2018-2023)
7.1.3 Market Forecast (2024-2032)
7.2 Protein Biomarkers
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2018-2023)
7.2.3 Market Forecast (2024-2032)
7.3 Glyco-Biomarkers
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2018-2023)
7.3.3 Market Forecast (2024-2032)
8 United States Cancer Biomarkers Market - Breakup by Cancer Type
8.1 Breast Cancer
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2018-2023)
8.1.3 Market Forecast (2024-2032)
8.2 Lung Cancer
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2018-2023)
8.2.3 Market Forecast (2024-2032)
8.3 Colorectal Cancer
8.3.1 Overview
8.3.2 Historical and Current Market Trends (2018-2023)
8.3.3 Market Forecast (2024-2032)
8.4 Prostate Cancer
8.4.1 Overview
8.4.2 Historical and Current Market Trends (2018-2023)
8.4.3 Market Forecast (2024-2032)
8.5 Stomach Cancer
8.5.1 Overview
8.5.2 Historical and Current Market Trends (2018-2023)
8.5.3 Market Forecast (2024-2032)
8.6 Others
8.6.1 Historical and Current Market Trends (2018-2023)
8.6.2 Market Forecast (2024-2032)
9 United States Cancer Biomarkers Market - Breakup by Application
9.1 Diagnostics
9.1.1 Overview
9.1.2 Historical and Current Market Trends (2018-2023)
9.1.3 Market Forecast (2024-2032)
9.2 Prognostics
9.2.1 Overview
9.2.2 Historical and Current Market Trends (2018-2023)
9.2.3 Market Forecast (2024-2032)
9.3 Risk Assessment
9.3.1 Overview
9.3.2 Historical and Current Market Trends (2018-2023)
9.3.3 Market Forecast (2024-2032)
9.4 Drug Discovery and Development
9.4.1 Overview
9.4.2 Historical and Current Market Trends (2018-2023)
9.4.3 Market Forecast (2024-2032)
9.5 Others
9.5.1 Historical and Current Market Trends (2018-2023)
9.5.2 Market Forecast (2024-2032)
10 United States Cancer Biomarkers Market - Breakup by End User
10.1 Hospitals
10.1.1 Overview
10.1.2 Historical and Current Market Trends (2018-2023)
10.1.3 Market Forecast (2024-2032)
10.2 Academic and Research Institutions
10.2.1 Overview
10.2.2 Historical and Current Market Trends (2018-2023)
10.2.3 Market Forecast (2024-2032)
10.3 Ambulatory Surgical Centers
10.3.1 Overview
10.3.2 Historical and Current Market Trends (2018-2023)
10.3.3 Market Forecast (2024-2032)
10.4 Diagnostic Laboratories
10.4.1 Overview
10.4.2 Historical and Current Market Trends (2018-2023)
10.4.3 Market Forecast (2024-2032)
10.5 Others
10.5.1 Historical and Current Market Trends (2018-2023)
10.5.2 Market Forecast (2024-2032)
11 United States Cancer Biomarkers Market – Breakup by Region
11.1 Northeast
11.1.1 Overview
11.1.2 Historical and Current Market Trends (2018-2023)
11.1.3 Market Breakup by Profiling Technology
11.1.4 Market Breakup by Biomolecule
11.1.5 Market Breakup by Cancer Type
11.1.6 Market Breakup by Application
11.1.7 Market Breakup by End User
11.1.8 Key Players
11.1.9 Market Forecast (2024-2032)
11.2 Midwest
11.2.1 Overview
11.2.2 Historical and Current Market Trends (2018-2023)
11.2.3 Market Breakup by Profiling Technology
11.2.4 Market Breakup by Biomolecule
11.2.5 Market Breakup by Cancer Type
11.2.6 Market Breakup by Application
11.2.7 Market Breakup by End User
11.2.8 Key Players
11.2.9 Market Forecast (2024-2032)
11.3 South
11.3.1 Overview
11.3.2 Historical and Current Market Trends (2018-2023)
11.3.3 Market Breakup by Profiling Technology
11.3.4 Market Breakup by Biomolecule
11.3.5 Market Breakup by Cancer Type
11.3.6 Market Breakup by Application
11.3.7 Market Breakup by End User
11.3.8 Key Players
11.3.9 Market Forecast (2024-2032)
11.4 West
11.4.1 Overview
11.4.2 Historical and Current Market Trends (2018-2023)
11.4.3 Market Breakup by Profiling Technology
11.4.4 Market Breakup by Biomolecule
11.4.5 Market Breakup by Cancer Type
11.4.6 Market Breakup by Application
11.4.7 Market Breakup by End User
11.4.8 Key Players
11.4.9 Market Forecast (2024-2032)
12 United States Cancer Biomarkers Market – Competitive Landscape
12.1 Overview
12.2 Market Structure
12.3 Market Player Positioning
12.4 Top Winning Strategies
12.5 Competitive Dashboard
12.6 Company Evaluation Quadrant
13 Profiles of Key Players
13.1 Company A
13.1.1 Business Overview
13.1.2 Product Portfolio
13.1.3 Business Strategies
13.1.4 SWOT Analysis
13.1.5 Major News and Events
13.2 Company B
13.2.1 Business Overview
13.2.2 Product Portfolio
13.2.3 Business Strategies
13.2.4 SWOT Analysis
13.2.5 Major News and Events
13.3 Company C
13.3.1 Business Overview
13.3.2 Product Portfolio
13.3.3 Business Strategies
13.3.4 SWOT Analysis
13.3.5 Major News and Events
13.4 Company D
13.4.1 Business Overview
13.4.2 Product Portfolio
13.4.3 Business Strategies
13.4.4 SWOT Analysis
13.4.5 Major News and Events
13.5 Company E
13.5.1 Business Overview
13.5.2 Product Portfolio
13.5.3 Business Strategies
13.5.4 SWOT Analysis
13.5.5 Major News and Events
Company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.
14 United States Cancer Biomarkers Market - Industry Analysis
14.1 Drivers, Restraints, and Opportunities
14.1.1 Overview
14.1.2 Drivers
14.1.3 Restraints
14.1.4 Opportunities
14.2 Porters Five Forces Analysis
14.2.1 Overview
14.2.2 Bargaining Power of Buyers
14.2.3 Bargaining Power of Suppliers
14.2.4 Degree of Competition
14.2.5 Threat of New Entrants
14.2.6 Threat of Substitutes
14.3 Value Chain Analysis
15 Appendix